Guinea-Bissau Halts U.S.-Funded Hepatitis B Infant Study Linked to RFK Jr.

Guinea-Bissau has suspended a planned U.S.-funded study of a hepatitis B vaccine in infants after widespread ethical objections from public health researchers. The controversy followed the Centers for Disease Control and Prevention’s approval in January 2026 of a $1.6 million grant for a trial involving 14,000 newborns, days after Health Secretary Robert F. Kennedy Jr. rescinded the agency’s long-standing recommendation that all infants receive a birth dose. The study, led by Danish investigators, would have delayed the vaccine until six weeks for roughly half of participants and would not have screened pregnant women for hepatitis B. The host government’s decision halts recruitment and effectively prevents the trial from proceeding as designed.

Key Takeaways

• The CDC approved a $1.6 million grant in January 2026 to support a trial of hepatitis B vaccine timing in Guinea-Bissau involving about 14,000 infants.
• About half of enrolled infants were to wait until six weeks for vaccination, a departure from the WHO and prior U.S. guidance recommending a birth dose.
• The trial design did not include routine screening of pregnant women for hepatitis B, a standard measure to protect newborns of infected mothers.
• Public health researchers in Africa and the United States condemned the protocol as ethically problematic under international research norms.
• Guinea-Bissau’s authorities announced a suspension; a Trump administration health official also said the study had been paused.
• HHS spokeswoman Emily Hilliard defended the proposal as aiming to answer questions about vaccine effects and meeting scientific and ethical standards.
• The dispute highlights tensions between national policy shifts and global public-health norms, with potential consequences for vaccine confidence and research partnerships.

Background

Hepatitis B is endemic in parts of West Africa, and neonatal infection carries a high risk of chronic liver disease, cirrhosis, and liver cancer later in life. The World Health Organization and long-standing public-health practice recommend administering a hepatitis B vaccine dose at birth to prevent mother-to-child transmission. In Guinea-Bissau, where health infrastructure is constrained, routine birth-dose coverage remains an important preventive measure for thousands of newborns each year.

In January 2026 the U.S. Department of Health and Human Services moved to rescind the CDC’s formal recommendation that every newborn receive a hepatitis B birth dose—an action led by Health Secretary Robert F. Kennedy Jr. That policy change preceded the CDC’s approval of a $1.6 million grant for a trial run by Danish investigators to study timing effects, prompting immediate scrutiny from epidemiologists and research-ethics experts. International research ethics frameworks require that clinical trials provide participants the prevailing standard of care unless a compelling, well-justified exception exists; critics argued the proposed protocol did not meet that bar.

Main Event

The approved study planned to enroll approximately 14,000 infants in Guinea-Bissau and compare outcomes between infants given a birth dose and those whose first dose was deferred until six weeks. Under the trial design, about half of participants would not receive the vaccine at birth, and pregnant women would not be routinely screened for hepatitis B infection. That omission drew particular concern because identifying infected mothers enables prompt newborn vaccination and additional prophylaxis where available.

Public-health researchers in Africa and the United States quickly condemned the design, arguing it contravened accepted ethical standards for human-subjects research. Critics noted that delaying vaccination for a substantial group of newborns in a high-prevalence setting could increase the risk of preventable infections. Within days of the outcry, Guinea-Bissau’s authorities announced the study could not go forward under its proposed protocol, and a U.S. administration official said the trial had been paused.

HHS responded publicly through spokesperson Emily Hilliard, stating the project aimed to answer unresolved questions about the vaccine’s effects and asserting the protocol had been based on “the highest scientific and ethical standards.” Danish investigators involved in the proposal have defended the scientific rationale for studying different timing strategies, but the host-country suspension precludes enrollment while ethical and procedural concerns remain unsettled.

Analysis & Implications

The episode underscores a central tension in global health research: the need to generate evidence in diverse settings while upholding local standards of care and international ethics norms. When a study’s control arm deviates from a widely accepted preventive measure—here, the birth-dose vaccination—regulators and ethics boards require clear justification that the trial cannot do harm and that participants receive protections equivalent to the standard of care. The absence of routine maternal screening in the protocol removes a widely recognized safeguard and undermines those justifications.

Politically, the controversy arrives at a sensitive moment. A policy reversal at a leading U.S. public-health agency can influence partner institutions’ willingness to collaborate and may sow confusion among health workers and communities about vaccine recommendations. In settings with limited health literacy or fragile trust in institutions, such confusion can translate into lower routine immunization uptake for other vaccines as well, with far-reaching consequences for child health.

Operationally, the suspension is likely to delay or cancel the collection of the planned trial data. That outcome means unanswered questions about timing will persist, but it also preserves current standards of neonatal protection. For funders and investigators, the incident may prompt stricter pre-implementation ethics review processes, stronger host-country engagement, and clearer protocols for maternal screening and post-trial access to care.

Comparison & Data

The table highlights where the trial protocol diverged from global norms: delayed dosing for a substantial subgroup and omission of maternal screening. Those differences explain much of the ethical concern, because both elements directly affect the risk of vertical transmission. In contexts with limited newborn follow-up or constrained health services, timely birth-dose vaccination and maternal testing are central to prevention strategies.

Reactions & Quotes

Public statements and attributed remarks polarized around whether the proposed design met ethical standards and what the suspension means for global research.

“The study design was based on the highest scientific and ethical standards,”

Emily Hilliard, HHS spokeswoman

This statement from HHS framed the trial as scientifically justified and ethically reviewed; it came as the department sought to defend the grant in the face of international criticism. Hilliard’s comment reiterated the administration’s position that the research aimed to address outstanding questions about vaccine effects.

“The study has been paused,”

Trump administration health official

An administration official confirmed a pause shortly after public outcry. That confirmation signaled internal concern and reflected how quickly host-country and international criticism can halt studies that lack broad ethical acceptance.

Unconfirmed

• Whether Robert F. Kennedy Jr. directly authorized the specific grant decision beyond rescinding the CDC birth-dose recommendation is not independently verified here.
• The exact internal CDC deliberations and ethics-board opinions that led to grant approval have not been publicly released.
• It is not yet clear whether the Danish investigators will redesign the protocol to meet host-country and international ethics expectations or withdraw the proposal entirely.

Bottom Line

The suspension of the Guinea-Bissau trial illustrates how departures from global standards of care—especially in vulnerable populations—trigger rapid ethical and political pushback. Although the proposed study sought to answer scientific questions about the timing of hepatitis B vaccination, its design choices, most notably delaying a birth dose for many infants and omitting routine maternal screening, raised credible ethical concerns that the host country could not accept.

For global health actors, the episode is a cautionary example: sound science must be paired with rigorous, transparent ethical review and meaningful host-country engagement before trials begin. Policymakers and funders should expect tighter scrutiny of research protocols that alter established preventive practices in high-risk settings, and communities will rightly demand that newborns continue to receive proven protections while evidence is gathered.

Sources

• The New York Times — news report on trial approval, controversy, and suspension (news)
• World Health Organization: Hepatitis B factsheet — international public health agency guidance on birth-dose vaccination (official guidance)
• U.S. Centers for Disease Control and Prevention: Hepatitis B — background on vaccination recommendations (U.S. public health agency)